• Therapeutic Category
  • Pharmaceutical Form : Eye Drops
  • Composition : Prednisolone acetate 5 mg+Neomycin (as sulfate) 3.5 mg+ Polymyxin B sulfate 10000 IU
  • Active Substance : Prednisolone acetate +Neomycin (as sulfate) + Polymyxin B sulfate


Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing.

Since corticosteroids may inhibit the body’s defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.

The anti-infective components in ophthalmic suspension are included to provide action against specific organisms susceptible to them. Neomycin sulfate and polymyxin B sulfate are considered active against the following microorganisms: Staphylococcus aureus; Escherichia coli; Hemophilus influenza; Klebsiella/ Enterobacter species; Neisseria species; and Pseudomonas aeruginosa.


A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens:

Staphylococcus aureus; Escherichia coli; Hemophilus influenzae; Klebsiella/ Enterobacter species; Neisseria species; and Pseudomonas aeruginosa.

The product does not provide adequate coverage against: Serratia marcescens; Streptococci, including Streptococcus pneumonia


Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye.

Fungal diseases of the ocular structures. Hypersensitivity to a component of the medication. (Hypersensitivity to the antibiotic component occurs at a higher rate than for other components).

The use of these combinations is always contraindicated after uncomplicated removal of a corneal foreign body.


TO TREAT THE EYE: Instill 1 or 2 drops every 3 or 4 hours, or more frequently as required.

Acute infections may require administration every 30 minutes, with frequency of administration reduced as the infection is brought under control.

TO TREAT THE LIDS: Instill 1 or 2 drops in the eye every 3 to 4 hours, close the eye and rub the excess on the lids and lid margins.


Store at (15 – 25) ˚C, Protect from freezing.


Bottle of 5 – 10 ml